Smart inhalers are devices, used for delivering various medications through inhalation. It is mainly a respiratory inhaler, equipped with a digital sensor, also known as connected inhalers. The sensor tracks data such as dosage timing, monitors the use of inhaler, and schedules the next dosage. These inhalers are able to generate alerts for daily dosage using smart devices like tablets or phones connected to the sensors via Bluetooth technology. These are designed to treat respiratory disorders such as chronic obstructive pulmonary diseases (COPD) and asthma. Some drugs are used in the inhalers include glucocorticoids, anti-cholinergic, beta-agonists and insulin etc.
According to study, “Global Smart Inhalers Market Size study, by product (inhalers and nebulizers), Indication (COPD and asthma), End-user (patients and R&D) and Regional Forecasts 2018-2025” the key companies operating in the global smart inhalers market are Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim GmbH, Vectura Group PLC, ResMed Inc. (Propeller Health), AstraZeneca PLC, Adherium Limited, Inspiro Medical Ltd., H&T Presspart Manufacturing Ltd., Aptar Pharma (AptarGroup, Inc.), Gecko Health Innovations, Inc., Cohero Health LLC, Glaxo SmithKine PLC, Novartis International AG, OPKO Health Inc., 3M Drug Delivery Systems, Crux Product Design Ltd, e-pill LLC, Glenmark Pharmaceuticals, OMRON Healthcare Europe B.V, PARI GmbH, Tri-Med Inc., Philips Respironics, Qualcomm Life, Shenzhen Bi-Rich Medical Devices Co., Ltd., Sensirion AG. The leading manufacturers are focusing on collaborating with digital & software companies in order to serve the targeted population. Furthermore, such collaborations also help manufacturers to launch their products more conveniently as well as augment their distribution channels.
Based on product type, smart inhalers market is segmented into nebulizers and inhalers. Inhalers segment is further sub-segmented into metered dose inhalers (MDIs) and dry powder inhalers (DPIs). MDIs maintain the amount of dosage used per inhalation for medication while DPIs deliver medications for instance corticosteroids directly to the lungs and are breathe activated. Based on indication type, market is segmented into COPD and asthma. Based on distribution channel, market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. In addition, based on end-use, market is segmented into hospitals & clinics, research institute and respiratory care centers.
The smart inhalers market is driven by increase in air pollution, followed by rise in prevalence of COPD and asthma diseases, increase in population susceptible to indoor air pollutants and technological advancements in the development of better smart inhaler devices & systems. However, overall high cost of asthma and COPD treatment and misusing data & data privacy may impact the market. Moreover, increase in focus towards advanced treatment protocols is a key opportunity for market.
Based on geography, the North-American region holds major share, followed by European region in smart inhalers market owing to high awareness about the use of digital devices for appropriate disease management, rise in adoption of smart inhaler device, high technological innovations in healthcare sector, and growth in adoption of IOT in healthcare industry in the region. The Asian-Pacific region is expected to witness higher growth rate due to growth in population affected with respiratory diseases caused by rise in air pollution over the forecast period. It is projected that the market will be reached at US $829.3 million by 2025.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications